Tamoxifen fulfils all criteria18 for timely repurposing as a symptomatic treatment for XLMTM, either as a monotherapy or combined with AAV-MTM1 restoration or DNM2 downregulation approaches that will hopefully prove efficacious in clinical trials. This evidence concerns the gene DNM2 and X-linked myotubular myopathy.